|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | Graphical user interface, website  Description automatically generated | | | |  | | --- | | **BULLETIN**  **What Massachusetts COVID-19 Vaccine Providers Need to Know**  **Week of 3/15/2023** | | | **LATEST NUMBERS**   * As of 3/15/2023 **5,636,278** people in Massachusetts have been fully vaccinated.   **LATEST NEWS**  **Moderna Monovalent COVID-19 Products Expiring in April**   * All Moderna adult (12+) and pediatric (6-11) monovalent COVID-19 vaccines will reach their expiry in early April. * Ordering for Moderna adult (12+) and pediatric (6-11) **monovalent** COVID-19 vaccines will end on March 13. * Ordering for Moderna **bivalent** vaccines for all age groups will remain available. * Administration sites should be mindful of patients starting their primary series with Moderna adult (12+) or pediatric (6-11) monovalent vaccines. Depending on the date, they may not be able to complete their primary series with this product. In this case, a different COVID-19 vaccine may be administered to complete the primary series at a minimum interval of 28 days from the last COVID-19 vaccine dose. Please read [CDC guidance on interchanging COVID-19 vaccines](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html*Interchangeability__;Iw!!CUhgQOZqV7M!k0VnS8ob8atrjcHhih_eRXrqUrKI0g6B1cnu6T6ghYSUjO-TYQ865mN8ywLtxHlq4pKiDufLANttXoAXIqFvUxXDZQ$).   Pfizer (12+ and 5-11) and Novavax (12+) monovalent vaccines remain available for ordering for primary series vaccination. There is an ample supply of both products, and providers can order additional supply.  **Moderna <6 Bivalent Minimum Order Quantity**  The minimum order quantity for Moderna <6 Bivalent (NDC # 80777-0283-99) vaccines has been reduced from 100 doses to 20 doses. Sites are now able order Moderna <6 Bivalent vaccines by increments of 20 doses. Please note that if your site orders 20 doses of Moderna <6 Bivalent vaccine, you will receive one carton, containing 20 doses in 10 two-dose vials.  **Commercialization of COVID-19 products**  HHS recently published a [question-and-answer document](https://urldefense.com/v3/__https:/immunizationmanagers.us16.list-manage.com/track/click?u=13b4fdc9ac0078e4c57522c2b&id=c4349edb49&e=4f158a4069__;!!CUhgQOZqV7M!mOJ1HacJneXLSjQ5ZfhT0d9FRTQ70-wNRhMBaNIFv3Zzh-ju5wb8TNlskW5-iCHlfrsxXy2c4hkRTipWdV-sypc0DJ6wA9E$) with frequently asked questions on the commercialization of COVID-19 medical countermeasures.  **WHO TO VACCINATE**  COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. There is currently no FDA-approved or FDA-authorized COVID-19 vaccine for children younger than age 6 months.  People can stay [up to date](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html) with COVID-19 vaccination by completing a primary series and receiving the most recent booster dose recommended for them by CDC (see [Table 2](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html?ACSTrackingID=USCDC_2120-DM91977&ACSTrackingLabel=Updated%20Guidance%3A%20Interim%20Clinical%20Considerations%20for%20Use%20of%20COVID-19%20Vaccines&deliveryName=USCDC_2120-DM91977#table-02) and [Table 3](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html?ACSTrackingID=USCDC_2120-DM91977&ACSTrackingLabel=Updated%20Guidance%3A%20Interim%20Clinical%20Considerations%20for%20Use%20of%20COVID-19%20Vaccines&deliveryName=USCDC_2120-DM91977#table-03)).  See Appendices B ([People who received COVID-19 vaccine outside the United States](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-b)) and C ([People who received COVID-19 vaccine as part of a clinical trial](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-c)) for recommendations for these populations.  **Primary series vaccination**  For primary series vaccination, **three monovalent COVID-19 vaccines** (listed in alphabetical order by manufacturer), are recommended: Moderna, Novavax, and Pfizer-BioNTech.  People ages 6 months and older are recommended to complete a primary series.  Monovalent vaccines should be used for the primary series, with one EXCEPTION: Children ages 6 months through 4 years who received 2 doses of a monovalent Pfizer vaccine should receive a bivalent Pfizer vaccine as their third primary series dose.  Vaccine products made by the same manufacturer should be used for all doses of the primary series (see [Interchangeability of COVID-19 vaccine products](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#Interchangeability)).  **Booster vaccination**  Monovalent mRNA vaccines are not authorized as a booster dose.  People ages 6 months and older are recommended to receive 1 bivalent mRNA booster dose after completion of any FDA-approved or FDA-authorized primary series or previously received monovalent booster dose(s) with one EXCEPTION: children 6 months through 4 years who receive a3-dose Pfizer primary series are not authorized to receive a booster doseat this time regardless of which Pfizer vaccine (i.e., a monovalent or bivalent) was administered for the third primary series dose.  A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in**limited situations**in people ages 18 years and older who completed any FDA-approved or FDA-authorized monovalent primary series, have not received any previous booster dose(s), and are unable (i.e., contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.  **Bivalent booster product varies by age**   * Ages **6 months–4 years** and completed the **Moderna primary series**: 1 **bivalent Moderna booster** dose. * Ages **6 months–4 years** and completed **Pfizer primary series**: **No booster** dose is recommended at this time. * Age **5 years** and completed **Moderna primary series**: **1 bivalent mRNA booster dose (Moderna or Pfizer)**. * Age **5 years** and completed **Pfizer primary series**: **1 bivalent Pfizer booster** dose. (Regardless of whether the third primary series dose was a monovalent or bivalent Pfizer vaccine) * Ages **6 years and older** and **any primary series**: **1 bivalent mRNA booster dose (Moderna or Pfizer)**.   **VACCINE ADMINISTRATION RECOMMENDATIONS**  **Four COVID-19 vaccines are currently approved under a BLA or authorized under an EUA by the FDA:**  The following COVID-19 vaccines, categorized into three [vaccine types](https://www.cdc.gov/vaccines/hcp/conversations/understanding-vacc-work.html), are currently approved under a BLA or authorized under an EUA by the FDA:   * [mRNA vaccines](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html)   + Moderna COVID-19 Vaccine/SPIKEVAX and Moderna COVID-19 Vaccine, Bivalent   + Pfizer-BioNTech COVID-19 Vaccine/COMIRNATY and Pfizer-BioNTech COVID-19 Vaccine, Bivalent * [Protein subunit vaccine](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/proteinsubunit.html)   + Novavax COVID-19 Vaccine, Adjuvanted * [Adenovirus vector vaccine](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.html)   + Janssen (Johnson & Johnson) COVID-19 VaccineCOVID-19 vaccine products are formulated as follows: * Monovalent vaccine: The vaccine product is based on the original (ancestral) strain of SARS-CoV-2 * Bivalent vaccine: The vaccine product is based on the original (ancestral) strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 (BA.4/BA.5) variants of SARS-CoV-2   None of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines.  Janssen COVID-19 Vaccine is authorized for adults ages 18 years and older in [certain limited situations](https://www.fda.gov/media/146304/download) due to safety considerations (see [Appendix A](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)).  COVID-19 vaccine-specific [FDA fact sheets](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines) and [U.S. COVID-19 Vaccine Product Information](https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html) can be consulted for a full list of ingredients and information on the conditions of use, storage and handling, preparation, and administration procedures.  **COVID-19 vaccine formulations currently approved or authorized in the United States**  The table below can be found [here](https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf). | | |  | | --- | |  | | |  | | |  | | --- | |  | | | |  | | --- | | **COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised**  For primary series vaccination, Moderna, Novavax, and Pfizer COVID-19 vaccines are recommended; only monovalent vaccines are approved or authorized for primary series doses. The same vaccine product should be used for all doses of the primary series (see [Interchangeability of COVID-19 vaccine products](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#Interchangeability)). The graphic below is available [here](https://www.cdc.gov/vaccines/covid-19/images/COVID19-vaccination-schedule-most-people.png) | | | |  | | --- | |  | | | |  | | --- | | **Considerations for intervals for mRNA COVID-19 vaccine primary series**  **An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months-64 years, especially for males ages 12–39 years.** COVID-19 vaccines are FDA-approved or FDA-authorized for a 3-week (Pfizer vaccine) or 4-week (Moderna vaccine) interval between the first and second dose. A 3- or 4-week interval continues to be the recommended interval for people who are moderately or severely immunocompromised, adults ages 65 years and older, and in situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about [COVID-19 community levels](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/science/community-levels.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLnC1H_DIA$) or an individual’s higher risk for severe disease).  mRNA COVID-19 vaccines are safe and effective at the FDA-approved or FDA-authorized intervals, but a longer interval may be considered for some populations. While absolute risk remains small, the risk for myocarditis is higher for males ages 12-39 years, and this risk might be reduced by extending the interval between the first and second dose. [Some studies](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-04/11-COVID-Moulia-508.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLm2YAf_jw$) in adolescents (ages 12-17 years) and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. Extending the interval beyond 8 weeks has not been shown to provide additional benefit. **In summary, an 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months-64 years, especially for males ages 12–39 years.**    **Evusheld no longer authorized for use in the United States**  As of January 26, 2023, tixagevimab/cilgavimab (EVUSHELD), a combination of two monoclonal antibodies, is [not currently authorized](https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us) for use in the United States. EVUSHELD was previously recommended for pre-exposure prophylaxis to supplement vaccine protection; however, SARS-CoV-2 variants currently circulating in the United States are [resistant to EVUSHELD™](https://www.cdc.gov/mmwr/volumes/72/wr/mm7205e3.htm).  **COVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised**  People with immunocompromising conditions or people who take immunosuppressive medications or therapies are [at increased risk for severe COVID-19](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLkIiPeCZA$). Because the immune response following COVID-19 vaccination may differ in people who are moderately or severely immunocompromised at the time of vaccination, specific guidance for this population is provided.  For primary series vaccination, Moderna, Novavax, and Pfizer COVID-19 vaccines are recommended; only monovalent vaccines are approved or authorized for primary series doses. The same vaccine product should be used for all doses of the primary series (see [Interchangeability of COVID-19 vaccine products](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#Interchangeability)).  For booster vaccination, Moderna and Pfizer are recommended. Recommendations vary based on age and primary series product.  People who are or who become moderately or severely immunocompromised should follow the COVID-19 vaccination schedule according to their age and immune status at the time of eligibility for that dose. For example, people who become moderately or severely immunocompromised after completing a 2-dose mRNA primary series do not need additional primary doses; however, they should follow the schedule for people who are moderately or severely immunocompromised for the booster dose. The graphic below is available [here](https://www.cdc.gov/vaccines/covid-19/images/COVID19-vaccination-schedule-immunocompromised.png).  Graphical user interface  Description automatically generated | | | |  | | --- | |  | | |  | |  | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | **VACCINE MANAGEMENT**  **Pfizer 12+ bivalent single dose vials now available for ordering by Primary Care Provider (PCP) Sites**  The Pfizer bivalent vaccine formulation for 12+ is now available in single dose vials. Due to limited quantities of this formulation, it is currently being made available only to PCP sites (pediatricians, family practices, internal medicine offices, community health centers). To add this vaccine formulation/packaging click on the “[add a vaccine](https://resources.miisresourcecenter.com/trainingcenter/New%20Order_2018_Mini%20Guide.pdf)” button in the lower left-hand corner of the ordering screen.  See below for additional information about the SDV presentation of the Pfizer (12+) Bivalent COVID-19 Vaccine:   * The order quantity is 50 doses.   + All single-dose vials, plan to use every single dose. * Product dimensions: 1.47in x 1.535in x 3.504in   + Storage space required equals that of a 300-dose MDV order * **SDVs will not include ancillary kits**. SDVs do not require the use of low-dead-volume syringes. * This product is new packaging, not a new vaccine. Storage and handling requirements remain the same as the Pfizer bivalent multi-dose vial. (Store at ultra-low temperature until expiry, may refrigerate up to 10 weeks within the expiry period).   **COVID-19 Ancillary Kit Opt-Out Intentions Survey Closed**  The MDPH survey regarding provider sites intentions to opt-out of receiving COVID-19 vaccine ancillary kits has now officially closed. Please note that all submissions have been processed by the Vaccine Management Unit and your COVID-19 ancillary kit intention has been recorded for your practice. If your site had elected to opt-out of receiving COVID-19 ancillary kits, this change will be applied to your site’s orders moving forward. Please note that the following COVID-19 formulation ancillary kits cannot be opted-out of due to the need for vaccine reconstitution and the inability for the diluent to be shipped without the complete ancillary kit.   * COVID-19 Pfizer <5 (monovalent), NDC: 59267-0078-04 * COVID-19 Pfizer Bivalent <5, NDC: 59267-0609-02 * COVID-19 Pfizer 5-11 (monovalent), NDC: 59267-1055-04 * COVID-19 Pfizer Bivalent 5-11, NDC: 59267-0565-02   **Novavax Available to Order in MIIS**  The Novavax COVID-19 vaccine formulation is once again orderable in the MIIS system. Please note that all doses of Novavax that are available to order have an expiration date of 4/30/23. If your site is trying to order additional doses of Novavax, but the formulation is not appearing on your ordering table in MIIS, your site will need to click the “add a vaccine” button in the lower left-hand corner of the ordering page to place your order. Please review the additional information below for further clarification.  **Trade Name**: Novavax COVID-19 Vaccine  **NDC Number**: 80631-0100-10  **Manufacturer**: Novavax, Inc.  **Packaging**: 100 doses- 10 dose MDV  **Vaccine Inventory Management Reminder**  Proper vaccine inventory management is critical to ensure expired vaccines or vaccines past the Beyond Use Date (BUD) are not administered to patients. Vaccine inventory should be checked daily. During the daily check (1) review and compare your physical inventory to your MIIS inventory, (2) process storage and handling issues in the MIIS for all wasted or expired doses. Vaccine orders may be canceled or reduced due to MIIS inventory showing high inventory or expired vaccines. If you do have expired or wasted vaccines, be sure to process a vaccine storage and handling issue in the MIIS before placing your next vaccine order request.  **Watch for Expired Vaccine**  We continue to encourage you to properly manage and report your inventory:   * Practice first in/first out inventory management. * Store older vaccines to the front of the refrigerator or freezer unit. * Continually monitor vaccines to help reduce administration errors. * Verify expiry dates using the manufacturers’ online checkers:   + **Pfizer:** [https://lotexpiry.cvdvaccine.com](https://urldefense.com/v3/__https:/lotexpiry.cvdvaccine.com__;!!CUhgQOZqV7M!g1Yw5s9rP2l4dkC-7CD1gxNax-9_NEnMVlrrMsI7fKtol4z38iBzCVOWymrfdx2hFKkXG21JexZO0BFcRHYFXWo$)   + **Moderna:** [https://modernacovid19global.com/vial-lookup](https://urldefense.com/v3/__https:/modernacovid19global.com/vial-lookup__;!!CUhgQOZqV7M!g1Yw5s9rP2l4dkC-7CD1gxNax-9_NEnMVlrrMsI7fKtol4z38iBzCVOWymrfdx2hFKkXG21JexZO0BFc0u-dkYA$)   + **Novavax:** [https://us.novavaxcovidvaccine.com/hcp](https://urldefense.com/v3/__https:/us.novavaxcovidvaccine.com/hcp__;!!CUhgQOZqV7M!g1Yw5s9rP2l4dkC-7CD1gxNax-9_NEnMVlrrMsI7fKtol4z38iBzCVOWymrfdx2hFKkXG21JexZO0BFcSHj6TOA$)   + **Johnson and Johnson/Janssen:** [https://vaxcheck.jnj/](https://urldefense.com/v3/__https:/vaxcheck.jnj/__;!!CUhgQOZqV7M!g1Yw5s9rP2l4dkC-7CD1gxNax-9_NEnMVlrrMsI7fKtol4z38iBzCVOWymrfdx2hFKkXG21JexZO0BFcjMhtgo4$) * Ensure your inventory is up to date by reporting administered doses and processing storage and handling for expired or wasted vaccine. * Dispose of any expired or wasted vaccine.   **Expiry Date vs Beyond Use Date (BUD)**  The **expiration date** is set by the manufacturer and is the date by which the vaccine should be used. The expiration date assumes that the vaccine has been stored and handled according to the manufacturer’s guidance. Expiration dates cannot change based on how vaccine is being stored or when a vial is punctured. However, on occasion, the expiration date may be updated by the manufacturer as additional stability data become available.  **Beyond Use Date (BUD)** is the date of when the vaccine can no longer be used due to a change in storage temperature, reconstitution, puncturing the vial, etc. It is recommended to place a label with the BUD and the initials of the person making the calculation whenever a vaccine vial or box is moved to a different temperature storage unit, reconstituted, or had a vial punctured resulting in a chance in the BUD.  You can find BUD guidance and labels for [Moderna,](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/storage-handling-label.pdf) [Novavax](https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-bud-tracking-labels.pdf), [Janssen](https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/downloads/janssen-storage-handling-label.pdf), and [Pfizer](https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/storage-handling-label.pdf) from the CDC’s U.S. COVID-19 Vaccine Product Information webpage.  **Moderna Bivalent Ancillary supply kits – Adult or Pediatric**  Pediatric provider sites ordering the Moderna bivalent COVID-19 vaccine booster will be sent two pediatric ancillary kits per minimum dose order by default to accommodate double the number of doses provided in each vial. Family practices and other provider types will be sent one adult ancillary kit per minimum dose order.   * If you would like ancillary supply kits different than what is described above, please specify pediatric or adult kits requested in the notes section of your vaccine order.   **Ancillary Supply Kit Equipment and Expiration Dates**  The COVID-19 vaccine ancillary kit contents do NOT all expire on the same date. Do not discard the entire kit based on the date printed on the label as it does not apply to all the contents of the kit.   * The expiration date for masks and face shields is indicated on the ancillary supply kit label. * The expiration date for other supplies (needles, syringes, alcohol prep pads, etc.) are printed on the individual packaging. The expiration date printed on the kit’s label does NOT apply to supplies with an expiration date printed on the packaging.   Reminder: Check the expiration date BEFORE using any medical equipment. NEVER USE EXPIRED EQUIPMENT. Always discard expired items.  **COVID Vaccines Available for ordering in the MIIS**  All providers enrolled Massachusetts COVID-19 Vaccine Program (MCVP) are able to place routine orders for all of the following COVID-19 vaccine formulations through the Massachusetts Immunization Information System (MIIS).   |  |  |  |  | | --- | --- | --- | --- | | Brand | NDC | NDC Description | Minimum ordering size | | - | 59267-0078-04 | COVID-19 (Pfizer);(PED 6m-4y) MDV10;10-pk | 100 | | - | 59267-1055-04 | COVID-19 (Pfizer);(PED 5-11) MDV10;10-pk | 100 | | COMIRNATY | 00069-2025-10 | COVID-19; MDV6; 10-pack | 180 | | - | 59267-0304-02 | COVID-19 (Pfizer);BIVALENT;MDV6; 10-pack | 180 | | - | 59267-1404-02 | COVID-19(Pfizer);BIVALENT;SDV;10pk | 50 | | - | 59267-0565-02 | COVID-19 (Pfizer);BIVALENT;(PED 5-11) MDV10;10pk | 100 | | - | 59267-0609-02 | COVID-19 (Pfizer);BIVALENT;(PED 6m-4y) MDV10; 10-pack | 100 | | - | 80777-0279-99 | COVID-19 (Moderna) (PED 6m-5y) MDV10;10-pack | 100 | | - | 80777-0282-99 | COVID-19 (Moderna);BIVALENT;MDV5; 10-pack | 100 | | - | 80777-0283-99 | COVID-19 (Moderna); BIVALENT;(PED 6m-5y) MDV2;10-pack | 100 | | - | 80631-0100-10 | COVID-19 (Novavax); MDV10; 10-pack | 100 |  * Initial shipments of the Pfizer-BioNTech vaccine for children aged 6m–4 years may state “2y to <5y” or “6m to <5y” on the vial or carton labels. Please note that vials or cartons with labels that state “2y to <5y” can be used for children aged 6m through 4 years. * Pfizer-BioNTech vaccine vial labels and cartons may also state that a vial should be discarded 6 hours after the first dilution however as stated in the EUA Fact Sheet the timeframe for use post-dilution is actually 12 hours just like orange and gray cap Pfizer vaccine formulations.  |  | | --- | | **RESOURCES & LEARNING OPPORTUNITIES**  **Moderna’s COVID-19 Vaccine Training Webinars**  In February, Modernavaccine training webinars transitioned to a new series of regional webinars with expert panelists. There are currently no New England ones scheduled, that we are aware of.  **Pfizer COVID-19 Vaccine Training Webinars**  In January, Pfizer vaccine training webinars transitioned from live events to ON DEMAND content for all healthcare providers. They can be found at <https://www.pfizermedicalinformation.com/en-us/medical-updates>  **EUA Fact Sheets**  Once a new EUA Fact Sheet is issued, it must be used. Previous ones no longer contain accurate information.   * Moderna EUAscan be found on the FDA website[here](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines) * Pfizer EUAs can be found on the FDA website [here](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines) * Novavax EUAscan be found on the FDA website[here](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted) * Janssen EUAscan be found on the FDA website[here](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine)   **“At a Glance” Summaries**  The CDC “At a Glance” Summaries include Storage and Handling basics, Preparation and Administration Basics, and a Schedule graphic.   * Pfizer <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/vaccine-at-a-glance.pdf> * Moderna <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/vaccine-at-a-glance.pdf> * Novavax [https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-prep-admin-summary.pdf](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-prep-admin-summary.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLmS8GIhaA$)   **Standing Orders**   * CDC’s Moderna COVID-19 Vaccine info (including the standing orders below) <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html> * Moderna 6 months through 5 years of age <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/infant_standing-orders.pdf> * Moderna 6 through 11 years of age <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/6-11-standing-orders.pdf> * Moderna 12 years of age and older <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/12-17-standing-orders.pdf> * CDC’s Pfizer COVID-19 Vaccine info (including the standing orders below) <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html> * Pfizer 6 months through 4 years of age <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/infant-standing-orders.pdf> * Pfizer 5 through 11 years of age <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/Pfizer_PED_StandingOrders.pdf> * Pfizer, Monovalent and Bivalent: 12 years of age and older <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/gray-cap-Pfizer-BioNTech-standing-orders.pdf> * Novavax <https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-standing-orders.pdf>   **Helpful Reference Materials**   * [Interim COVID-19 Immunization Schedule](https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf) * [Summary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized or Approved in the United States](https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf) * [AAP’s Pediatric COVID-19 Vaccine Dosing Quick Reference Guide](https://urldefense.com/v3/__https:/downloads.aap.org/AAP/PDF/COVID*20Vaccine*20Dosing_Quick*20Reference.pdf__;JSUl!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLkQx_euEA$) * [Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group](https://www.cdc.gov/vaccines/covid-19/downloads/child-age-transition-508.pdf) * [Pfizer-BioNTech for Children who Transition from a Younger to Older Age Group](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLm3fhfIdw$) * [Vaccine administration errors and deviations (Appendix D)](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-d) * [FAQs for the Interim Clinical Considerations](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/faq.html) * [COVID-19 vaccination and SARS-CoV-2 infection](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#infection) * [People who received COVID-19 vaccine outside the United States (Appendix B)](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-b) * [People who received COVID-19 vaccine as part of a clinical trial (Appendix C)](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-c)  * [Triage of people with a history of allergies or allergic reactions (Appendix E)](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html" \l "appendix-e) * [Resources to Promote COVID-19 Vaccines for Children & Teens](https://www.cdc.gov/vaccines/covid-19/planning/children/resources-promote.html) (includes social media graphics, posters, videos, external partner resources) * [Stay Up to Date with COVID-19 Vaccines Including Boosters](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html) (the COVID19 booster tool can be found here also)   **Information for parents and caregivers:**   * [[Stay Up to Date with COVID-19 Vaccines Including Boosters|](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html) CDC](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html?CDC_AA_refVal=https*3A*2F*2Fwww.cdc.gov*2Fcoronavirus*2F2019-ncov*2Fvaccines*2Frecommendations*2Fadolescents.html__;JSUlJSUlJSU!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLkfB9jY2A$) * [Frequently Asked Questions about COVID-19 Vaccination in Children | CDC](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/vaccines/faq-children.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLl-eqIMAQ$) * [6 Things to Know about COVID-19 Vaccination for Children | CDC](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/planning/children/6-things-to-know.html?CDC_AA_refVal=https*3A*2F*2Fwww.cdc.gov*2Fvaccines*2Fcovid-19*2Fplanning*2Fchildren*2F10-things-to-know.html__;JSUlJSUlJSU!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLn4H4jdWg$) * [V-safe After Vaccination Health Checker | CDC](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLnDCjkUdQ$) * [COVID-19 Vaccine: Frequently Asked Questions | American Academy of Pediatrics](https://urldefense.com/v3/__https:/www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/covid-19-vaccine-for-children/about-the-covid-19-vaccine-frequently-asked-questions/__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLn2BtygXA$) |   **COVID-19 Vaccine Training Modules**  CDC’s four training modules (General Overview, Pfizer, Moderna, Janssen) can be found [here](https://urldefense.com/v3/__https:/www2.cdc.gov/vaccines/ed/covid19/__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLmgOEuTAw$).  **COVID-19 Vaccine Webinar Series**  CDC is offering a series of brief (15-20 minute) webinars addressing topics around COVID-19 vaccination. These interactive, web-based training modules offer a real-world perspective on different issues around COVID-19 vaccines. Topics range from routine clinical and vaccine safety information to guidance for on-site clinic vaccination activities and having conversations with vaccine recipients. Each webinar includes self-test practice questions and lists additional resources related to the topic discussed. The landing page for all mini webinars is here: <https://www.cdc.gov/vaccines/covid-19/training-education/webinars.html>  **CDC interactive tool for the public to assess if they are eligible for a booster dose of COVID-19 vaccine**  CDC has an interactive tool to help users identify whether they (or someone else) need to receive a booster dose of COVID-19 vaccine. The “Find Out When You Can Get Your Booster” tool asks a series of simple questions about age, immunocompromise, number and type of previous doses of COVID-19 vaccines, and how long ago they received the most recent vaccination. From these answers, the tool reports whether a booster dose may be beneficial and presents considerations for when to receive it. Find the tool [here](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html*when-you-can-get-booster__;Iw!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLkqIhXZbA$).  **Morbidity and Mortality Weekly Report**, better known as MMWR, is CDC’s primary publication for disseminating the science it produces. You can search by topics [here](https://www.cdc.gov/mmwr/mmwr_additional_resources.html?topics=%22Covid-19%22), and you will find the COVID-19 related reports [here](https://www.cdc.gov/mmwr/mmwr_additional_resources.html?topics=%22Covid-19%22).  **Recent CDC MMWRs**  [Effect of Predeparture Testing on Postarrival SARS-CoV-2–Positive Test Results Among International Travelers — CDC Traveler-Based Genomic Surveillance Program, Four U.S. Airports, March–September 2022](https://www.cdc.gov/mmwr/volumes/72/wr/mm7208a2.htm)  February 24, 2023MMWR. Morbidity and Mortality Weekly Report / Vol. 72 / No. 8 / P. 206–209  Download: [Article PDF](https://www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7208a2-H.pdf), [Full Issue PDF](https://www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7208-H.pdf)  [Notes from the Field: Aircraft Wastewater Surveillance for Early Detection of SARS-CoV-2 Variants — John F. Kennedy International Airport, New York City, August–September 2022](https://www.cdc.gov/mmwr/volumes/72/wr/mm7208a3.htm)  February 24, 2023MMWR. Morbidity and Mortality Weekly Report / Vol. 72 / No. 8 / P. 210–211  Download: [Article PDF](https://www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7208a3-H.pdf), [Full Issue PDF](https://www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7208-H.pdf)  [Notes from the Field: Epidemiologic Characteristics of SARS-CoV-2 Recombinant Variant XBB.1.5 — New York City, November 1, 2022–January 4, 2023](https://www.cdc.gov/mmwr/volumes/72/wr/mm7208a4.htm)  February 24, 2023MMWR. Morbidity and Mortality Weekly Report / Vol. 72 / No. 8 / P. 212–214  Download: [Article PDF](https://www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7208a4-H.pdf), [Full Issue PDF](https://www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7208-H.pdf)  **MDPH RESOURCES**  **Massachusetts Resources**   * [COVID-19 Vaccine main page](https://www.mass.gov/covid-19-vaccine) * COVID-19 vaccinations for [children ages 6 months to 4 years old](https://www.mass.gov/info-details/covid-19-vaccinations-for-children-ages-6-months-to-4-years-old) * COVID-19 vaccinations for [children ages 5-17](https://www.mass.gov/info-details/covid-19-vaccinations-for-children-and-youth-ages-5-17" \t "_blank) * Search for a COVID-19 vaccine at [vaxfinder.mass.gov](https://vaxfinder.mass.gov/) * COVID-19 [booster frequently asked questions](https://www.mass.gov/info-details/covid-19-booster-frequently-asked-questions) * COVID-19 Vaccine Resource Line/2-1-1 is available for individuals who are unable to use Vaxfinder, or have difficulty accessing the internet. Available in English and Spanish and has translators available in approximately 100 additional languages. * COVID-19 Vaccine Training and Education Resources for Providers: <https://www.mass.gov/info-details/covid-19-vaccine-training-and-education-resources-for-providers> * [Multilingual COVID-19 Materials](https://www.mass.gov/resource/multilingual-covid-19-materials). Resources related to Coronavirus Disease 2019 (COVID-19) in multiple languages. Includes videos and printables on topics like vaccine safety, pregnancy and the vaccine, and FAQs. * **The Massachusetts Vaccine Confidence Project website is now live!**   The Massachusetts Vaccine Confidence Project is a collaboration of the Immunization Initiative of the MCAAP, the Immunization Division of MDPH and the Massachusetts Adult Immunization Coalition. Visit the website at <https://massvaccineconfidenceproject.org/about-us/> for info, resources, and a calendar of events.  **Immunization Division Main Number**  For questions about immunization recommendations, disease reporting, etc.  Phone: 617-983-6800 (24/7 MDPH Epi line)  Fax: 617-983-6840  Website: <https://www.mass.gov/topics/immunization>  **MIIS Help Desk**  Phone: 617-983-4335  Fax: 857-323-8321  Email questions to: [miishelpdesk@mass.gov](mailto:miishelpdesk@mass.gov)  Website: <https://www.mass.gov/massachusetts-immunization-information-system-miis>  **MDPH Vaccine Unit**  Phone: 617-983-6828  Email questions to: [dph-vaccine-management@mass.gov](mailto:dph-vaccine-management@mass.gov)  Website: <https://www.mass.gov/service-details/vaccine-management>  **Color Help**  Email questions to: [colorhelp@mass.gov](mailto:colorhelp@mass.gov)  Website: <https://www.mass.gov/info-details/vaccine-clinic-management-platform>  **COVID-19 Email Box**  Email questions to: [COVID-19-Vaccine-Plan-MA@mass.gov](mailto:COVID-19-Vaccine-Plan-MA@mass.gov) | | | | | |